2024-03-28T08:44:57Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/637142022-11-17T02:08:08Zhdl_2115_20040hdl_2115_64361hdl_2115_64360hdl_2115_121Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancerFurusawa, JunHomma, AkihiroOnimaru, RikiyaSakashita, TomohiroYoshida, DaisukeHatakeyama, HiromitsuMizumachi, TakatsuguKano, SatoshiTsuchiya, KazuhikoYasuda, KoichiShirato, HirokiFukuda, SatoshiHead and neck cancerHypopharyngeal cancerIntra-arterialChemotherapyRadiotherapy490Objective: We retrospectively assessed the indications for superselective intra-arterial infusion of cisplatin with concomitant radiotherapy (RADPLAT) in patients with hypopharyngeal cancer (HPC). Methods: Between April 2000 and March 2013,41 previously untreated patients received superselective intra-arterial infusion of cisplatin (100-120 mg/m2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: During the median follow-up period of 5.5 years, a statistically significant difference in the 5-year overall survival was noted between patients with N0-1 (n = 14) and N2b-3 disease (n = 27). One-half of deaths were observed to be the result of distant metastasis. The 5-year local control and overall survival were significantly better in patients with unilateral than in those with bilateral primary tumors. All the patients with T4b disease (n = 3) died of disease within 2 years. Conclusion: Indications for RADPLAT in patients with HPC were defined as patients with unilateral tumors staged as T3-4a and N0-1.ElsevierJournal Articleapplication/pdfhttp://hdl.handle.net/2115/63714https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/63714/1/manuscript.pdf0385-8146Auris nasus larynx4264434482015-12enginfo:pmid/25933585info:doi/10.1016/j.anl.2015.04.003© 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/author